U.S. patent application number 13/290491 was filed with the patent office on 2012-05-17 for compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide.
This patent application is currently assigned to Vertex Pharmaceuticals Incorporated. Invention is credited to Charles William Rowe, Christopher R. Young.
Application Number | 20120122922 13/290491 |
Document ID | / |
Family ID | 38694761 |
Filed Date | 2012-05-17 |
United States Patent
Application |
20120122922 |
Kind Code |
A1 |
Young; Christopher R. ; et
al. |
May 17, 2012 |
COMPOSITIONS OF
N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-
-3-CARBOXAMIDE
Abstract
Pharmaceutical compositions including
N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-
-3-carboxamide (Compound 1) and methods of using such compositions
are described herein.
Inventors: |
Young; Christopher R.;
(Waltham, MA) ; Rowe; Charles William; (Medford,
MA) |
Assignee: |
Vertex Pharmaceuticals
Incorporated
Cambridge
MA
|
Family ID: |
38694761 |
Appl. No.: |
13/290491 |
Filed: |
November 7, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12471950 |
May 26, 2009 |
8076357 |
|
|
13290491 |
|
|
|
|
11748073 |
May 14, 2007 |
7553855 |
|
|
12471950 |
|
|
|
|
60799795 |
May 12, 2006 |
|
|
|
Current U.S.
Class: |
514/312 |
Current CPC
Class: |
A61P 7/02 20180101; A61K
47/32 20130101; A61P 43/00 20180101; A61P 25/00 20180101; A61P 3/06
20180101; A61P 3/00 20180101; A61P 27/02 20180101; A61P 11/00
20180101; A61P 7/00 20180101; A61P 25/28 20180101; A61P 9/00
20180101; A61P 25/16 20180101; A61K 31/435 20130101; A61K 9/08
20130101; A61K 31/47 20130101; A61K 47/10 20130101; A61P 37/02
20180101; C07D 215/233 20130101; A61P 1/00 20180101; A61P 19/04
20180101; A61P 25/14 20180101 |
Class at
Publication: |
514/312 |
International
Class: |
A61K 31/47 20060101
A61K031/47; A61P 11/00 20060101 A61P011/00; A61P 27/02 20060101
A61P027/02; A61P 25/16 20060101 A61P025/16; A61P 25/28 20060101
A61P025/28; A61P 3/06 20060101 A61P003/06; A61P 25/00 20060101
A61P025/00 |
Claims
1-20. (canceled)
21. A method of treating a CFTR mediated disease in a patient
comprising the step of administering to said patient a
pharmaceutical composition comprising: (i)
N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
or a pharmaceutically acceptable salt thereof; (ii) a liquid PEG
which has an average molecular weight of between about 200 and
about 600; and (iii) optionally, PVP.
22. The method according to claim 21, wherein said disease is
selected from cystic fibrosis, hereditary emphysema, hereditary
hemochromatosis, coagulation-fibrinolysis deficiencies, such as
protein C deficiency, Type 1 hereditary angioedema, lipid
processing deficiencies, such as familial hypercholesterolemia,
Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage
diseases, such as I-cell disease/pseudo-Hurler,
mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II,
polyendocrinopathy/hyperinsulinemia, Diabetes mellitus, Laron
dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism,
melanoma, glycanosis CDG type 1, hereditary emphysema, congenital
hyperthyroidism, osteogenesis imperfecta, hereditary
hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI),
neurohypophyseal DI, nephrogenic DI, Charcot-Marie Tooth syndrome,
Pelizaeus-Merzbacher disease, neurodegenerative diseases such as
Alzheimer's disease, Parkinson's disease, amyotrophic lateral
sclerosis, progressive supranuclear palsy, Pick's disease, several
polyglutamine neurological disorders such as Huntington,
spinocerebellar ataxia type I, spinal and bulbar muscular atrophy,
dentatorubral pallidoluysian atrophy, and myotonic dystrophy, as
well as spongiform encephalopathies, such as hereditary
Creutzfeldt-Jakob disease, Fabry disease,
Gerstmann-Straussler-Scheinker syndrome, COPD, dry-eye disease, and
Sjogren's disease.
23. The method according to claim 22, wherein said disease is
cystic fibrosis.
24. The method according to claim 21, wherein said pharmaceutical
composition is administered to a patient in need thereof once a
day.
Description
CLAIM OF PRIORITY
[0001] This application claims priority under 35 USC .sctn.119(e)
to U.S. Patent Application Ser. No. 60/799,795, filed on May 12,
2006, the entire contents of which are hereby incorporated by
reference.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to pharmaceutical compositions
of
N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-
-3-carboxamide and methods therewith.
BACKGROUND OF THE INVENTION
[0003] CFTR is a cAMP/ATP-mediated anion channel that is expressed
in a variety of cells types, including absorptive and secretory
epithelia cells, where it regulates anion flux across the membrane,
as well as the activity of other ion channels and proteins. In
epithelia cells, normal functioning of CFTR is critical for the
maintenance of electrolyte transport throughout the body, including
respiratory and digestive tissue. CFTR is composed of approximately
1480 amino acids that encode a protein made up of a tandem repeat
of transmembrane domains, each containing six transmembrane helices
and a nucleotide binding domain. The two transmembrane domains are
linked by a large, polar, regulatory (R)-domain with multiple
phosphorylation sites that regulate channel activity and cellular
trafficking.
[0004] The gene encoding CFTR has been identified and sequenced
(See Gregory, R. J. et al. (1990) Nature 347:382-386; Rich, D. P.
et al. (1990) Nature 347:358-362), (Riordan, J. R. et al. (1989)
Science 245:1066-1073). A defect in this gene causes mutations in
CFTR resulting in cystic fibrosis ("CF"), the most common fatal
genetic disease in humans. Cystic fibrosis affects approximately
one in every 2,500 infants in the United States. Within the general
United States population, up to 10 million people carry a single
copy of the defective gene without apparent ill effects. In
contrast, individuals with two copies of the CF associated gene
suffer from the debilitating and fatal effects of CF, including
chronic lung disease.
[0005] In patients with cystic fibrosis, mutations in CFTR
endogenously expressed in respiratory epithelia leads to reduced
apical anion secretion causing an imbalance in ion and fluid
transport. The resulting decrease in anion transport contributes to
enhanced mucus accumulation in the lung and the accompanying
microbial infections that ultimately cause death in CF patients. In
addition to respiratory disease, CF patients typically suffer from
gastrointestinal problems and pancreatic insufficiency that, if
left untreated, results in death. In addition, the majority of
males with cystic fibrosis are infertile and fertility is decreased
among females with cystic fibrosis. In contrast to the severe
effects of two copies of the CF associated gene, individuals with a
single copy of the CF associated gene exhibit increased resistance
to cholera and to dehydration resulting from diarrhea--perhaps
explaining the relatively high frequency of the CF gene within the
population.
[0006] Sequence analysis of the CFTR gene of CF chromosomes has
revealed a variety of disease causing mutations (Cutting, G. R. et
al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell
61:863:870; and Kerem, B-S. et al. (1989) Science 245:1073-1080;
Kerem, B-S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451).
To date, >1000 disease causing mutations in the CF gene have
been identified (http://www.genet.sickkids.on.ca/cftr/). The most
prevalent mutation is a deletion of phenylalanine at position 508
of the CFTR amino acid sequence, and is commonly referred to as
.DELTA.F508-CFTR. This mutation occurs in approximately 70% of the
cases of cystic fibrosis and is associated with a severe
disease.
[0007] The deletion of residue 508 in .DELTA.F508-CFTR prevents the
nascent protein from folding correctly. This results in the
inability of the mutant protein to exit the ER, and traffic to the
plasma membrane. As a result, the number of channels present in the
membrane is far less than observed in cells expressing wild-type
CFTR. In addition to impaired trafficking, the mutation results in
defective channel gating. Together, the reduced number of channels
in the membrane and the defective gating lead to reduced anion
transport across epithelia leading to defective ion and fluid
transport. (Quinton, P. M. (1990), FASEB J. 4: 2709-2727). Studies
have shown, however, that the reduced numbers of .DELTA.F508-CFTR
in the membrane are functional, albeit less than wild-type CFTR.
(Dalemans et al. (1991), Nature Lond. 354: 526-528; Denning et al.,
supra; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50).
In addition to .DELTA.F508-CFTR, other disease causing mutations in
CFTR that result in defective trafficking, synthesis, and/or
channel gating could be up- or down-regulated to alter anion
secretion and modify disease progression and/or severity.
[0008] Although CFTR transports a variety of molecules in addition
to anions, it is clear that this role (the transport of anions)
represents one element in an important mechanism of transporting
ions and water across the epithelium. The other elements include
the epithelial Na.sup.+ channel, ENaC, Na.sup.+/2Cl.sup.-/K.sup.+
co-transporter, Na.sup.+--K.sup.+-ATPase pump and the basolateral
membrane K.sup.+ channels, that are responsible for the uptake of
chloride into the cell.
[0009] These elements work together to achieve directional
transport across the epithelium via their selective expression and
localization within the cell. Chloride absorption takes place by
the coordinated activity of ENaC and CFTR present on the apical
membrane and the Na.sup.+--K.sup.+-ATPase pump and Cl- channels
expressed on the basolateral surface of the cell. Secondary active
transport of chloride from the luminal side leads to the
accumulation of intracellular chloride, which can then passively
leave the cell via Cl.sup.- channels, resulting in a vectorial
transport. Arrangement of Na.sup.+/2Cl.sup.-/K.sup.+
co-transporter, Na.sup.+--K.sup.+-ATPase pump and the basolateral
membrane K.sup.+ channels on the basolateral surface and CFTR on
the luminal side coordinate the secretion of chloride via CFTR on
the luminal side. Because water is probably never actively
transported itself, its flow across epithelia depends on tiny
transepithelial osmotic gradients generated by the bulk flow of
sodium and chloride.
[0010] In addition to cystic fibrosis, modulation of CFTR activity
may be beneficial for other diseases not directly caused by
mutations in CFTR, such as secretory diseases and other protein
folding diseases mediated by CFTR. These include, but are not
limited to, chronic obstructive pulmonary disease (COPD), dry eye
disease, and Sjogren's Syndrome. COPD is characterized by airflow
limitation that is progressive and not fully reversible. The
airflow limitation is due to mucus hypersecretion, emphysema, and
bronchiolitis. Activators of mutant or wild-type CFTR offer a
potential treatment of mucus hypersecretion and impaired
mucociliary clearance that is common in COPD. Specifically,
increasing anion secretion across CFTR may facilitate fluid
transport into the airway surface liquid to hydrate the mucus and
optimized periciliary fluid viscosity. This would lead to enhanced
mucociliary clearance and a reduction in the symptoms associated
with COPD. Dry eye disease is characterized by a decrease in tear
aqueous production and abnormal tear film lipid, protein and mucin
profiles. There are many causes of dry eye, some of which include
age, Lasik eye surgery, arthritis, medications, chemical/thermal
burns, allergies, and diseases, such as cystic fibrosis and
Sjogrens's syndrome. Increasing anion secretion via CFTR would
enhance fluid transport from the corneal endothelial cells and
secretory glands surrounding the eye to increase corneal hydration.
This would help to alleviate the symptoms associated with dry eye
disease. Sjogren's syndrome is an autoimmune disease in which the
immune system attacks moisture-producing glands throughout the
body, including the eye, mouth, skin, respiratory tissue, liver,
vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as
well as lung disease. The disease is also associated with
rheumatoid arthritis, systemic lupus, systemic sclerosis, and
polymypositis/dermatomyositis. Defective protein trafficking is
believed to cause the disease, for which treatment options are
limited. Modulators of CFTR activity may hydrate the various organs
afflicted by the disease and help to elevate the associated
symptoms.
[0011] As discussed above, it is believed that the deletion of
residue 508 in .DELTA.F508-CFTR prevents the nascent protein from
folding correctly, resulting in the inability of this mutant
protein to exit the ER, and traffic to the plasma membrane. As a
result, insufficient amounts of the mature protein are present at
the plasma membrane and chloride transport within epithelial
tissues is significantly reduced. In fact, this cellular phenomenon
of defective ER processing of ABC transporters by the ER machinery,
has been shown to be the underlying basis not only for CF disease,
but for a wide range of other isolated and inherited diseases. The
two ways that the ER machinery can malfunction is either by loss of
coupling to ER export of the proteins leading to degradation, or by
the ER accumulation of these defective/misfolded proteins [Aridor
M, et al., Nature Med., 5(7), pp 745-751 (1999); Shastry, B. S., et
al., Neurochem. International, 43, pp 1-7 (2003); Rutishauser, J.,
et al., Swiss Med Wkly, 132, pp 211-222 (2002); Morello, J P et
al., TIPS, 21, pp. 466-469 (2000); Bross P., et al., Human Mut.,
14, pp. 186-198 (1999)]. The diseases associated with the first
class of ER malfunction are cystic fibrosis (due to misfolded
.DELTA.F508-CFTR as discussed above), hereditary emphysema (due to
a1-antitrypsin; non Piz variants), hereditary hemochromatosis,
hoagulation-fibrinolysis deficiencies, such as protein C
deficiency, Type 1 hereditary angioedema, lipid processing
deficiencies, such as familial hypercholesterolemia, Type 1
chylomicronemia, abetalipoproteinemia, lysosomal storage diseases,
such as I-cell disease/pseudo-Hurler, Mucopolysaccharidoses (due to
lysosomal processing enzymes), Sandhof/Tay-Sachs (due to
.beta.-hexosaminidase), Crigler-Najjar type II (due to
UDP-glucuronyl-sialyc-transferase),
polyendocrinopathy/hyperinsulemia, Diabetes mellitus (due to
insulin receptor), Laron dwarfism (due to growth hormone receptor),
myleoperoxidase deficiency, primary hypoparathyroidism (due to
preproparathyroid hormone), melanoma (due to tyrosinase). The
diseases associated with the latter class of ER malfunction are
Glycanosis CDG type 1, hereditary emphysema (due to
.alpha.1-Antitrypsin (PiZ variant), congenital hyperthyroidism,
osteogenesis imperfecta (due to Type I, II, IV procollagen),
hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency
(due to .alpha.1-antichymotrypsin), Diabetes insipidus (DI),
neurophyseal DI (due to vasopvessin hormone/V2-receptor),
neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome
(due to peripheral myelin protein 22), Perlizaeus-Merzbacher
disease, neurodegenerative diseases such as Alzheimer's disease
(due to .beta.APP and presenilins), Parkinson's disease,
amyotrophic lateral sclerosis, progressive supranuclear plasy,
Pick's disease, several polyglutamine neurological disorders a such
as Huntington, spinocerebullar ataxia type I, spinal and bulbar
muscular atrophy, dentatorubal pallidoluysian, and myotonic
dystrophy, as well as spongiform encephalopathies, such as
hereditary Creutzfeldt-Jakob disease (due to prion protein
processing defect), Fabry disease (due to lysosomal
.alpha.-galactosidase A) and Straussler-Scheinker syndrome (due to
Prp processing defect).
[0012] In addition to up-regulation of CFTR activity, reducing
anion secretion by CFTR modulators may be beneficial for the
treatment of secretory diarrheas, in which epithelial water
transport is dramatically increased as a result of secretagogue
activated chloride transport. The mechanism involves elevation of
cAMP and stimulation of CFTR.
[0013] Although there are numerous causes of diarrhea, the major
consequences of diarrheal diseases, resulting from excessive
chloride transport are common to all, and include dehydration,
acidosis, impaired growth and death.
[0014] Acute and chronic diarrheas represent a major medical
problem in many areas of the world. Diarrhea is both a significant
factor in malnutrition and the leading cause of death (5,000,000
deaths/year) in children less than five years old.
[0015] Secretory diarrheas are also a dangerous condition in
patients of acquired immunodeficiency syndrome (AIDS) and chronic
inflammatory bowel disease (IBD). 16 million travelers to
developing countries from industrialized nations every year develop
diarrhea, with the severity and number of cases of diarrhea varying
depending on the country and area of travel.
[0016] Diarrhea in barn animals and pets such as cows, pigs and
horses, sheep, goats, cats and dogs, also known as scours, is a
major cause of death in these animals. Diarrhea can result from any
major transition, such as weaning or physical movement, as well as
in response to a variety of bacterial or viral infections and
generally occurs within the first few hours of the animal's
life.
[0017] The most common diarrheal causing bacteria is
enterotoxogenic E. coli (ETEC) having the K99 pilus antigen. Common
viral causes of diarrhea include rotavirus and coronavirus. Other
infectious agents include cryptosporidium, giardia lamblia, and
salmonella, among others.
[0018] Symptoms of rotaviral infection include excretion of watery
feces, dehydration and weakness. Coronavirus causes a more severe
illness in the newborn animals, and has a higher mortality rate
than rotaviral infection. Often, however, a young animal may be
infected with more than one virus or with a combination of viral
and bacterial microorganisms at one time. This dramatically
increases the severity of the disease.
[0019] Accordingly, there is a need for pharmaceutical compositions
of modulators of CFTR activity that can be used to modulate the
activity of CFTR in the cell membrane of a mammal.
[0020] There is a need for methods of treating CFTR-mediated
diseases using such pharmaceutical compositions.
SUMMARY OF THE INVENTION
[0021] The present invention relates to pharmaceutical compositions
of
N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-
-3-carboxamide (hereinafter "Compound 1") which has the structure
below:
##STR00001##
[0022] The pharmaceutical compositions of Compound 1 are useful for
treating or lessening the severity of a variety of CFTR-mediated
diseases.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] FIG. 1 is an X-Ray powder diffraction pattern of Compound
1.
[0024] FIG. 2 is the .sup.1H NMR spectrum of Compound 1.
[0025] FIG. 3 is the DSC trace of Compound 1.
DETAILED DESCRIPTION OF THE INVENTION
[0026] According to one embodiment, the present invention provides
a pharmaceutical composition comprising:
[0027] (i)
N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-ox-
oquinoline-3-carboxamide (Compound 1) or a pharmaceutically
acceptable salt thereof;
[0028] (ii) a suitable liquid PEG; and
[0029] (iii) optionally, a suitable viscosity enhancing agent.
[0030] As used herein, the phrase "suitable liquid PEG" means a
polyethylene glycol polymer that is in liquid form at ambient
temperature and is amenable for use in a pharmaceutical
composition. Such suitable polyethylene glycols are well known in
the art; see, e.g.,
http://www.medicinescomplete.com/mc/excipients/current, which is
incorporated herein by reference. Exemplary PEGs include low
molecular weight PEGs such as PEG 200, PEG 300, PEG 400, etc. The
number that follows the term "PEG" indicates the average molecular
weight of that particular polymer. E.g., PEG 400 is a polyethylene
glycol polymer wherein the average molecular weight of the polymer
therein is about 400.
[0031] In one embodiment, said suitable liquid PEG has an average
molecular weight of from about 200 to about 600. In another
embodiment, said suitable liquid PEG is PEG 400 (for example a PEG
having a molecular weight of form about 380 to about 420
g/mol).
[0032] In another embodiment, the present invention provides a
pharmaceutical composition comprising Compound 1 or a
pharmaceutically acceptable salt thereof; propylene glycol; and,
optionally, a suitable viscosity enhancing agent.
[0033] In another embodiment, the pharmaceutical compositions of
the present invention comprise a suitable viscosity enhancing agent
agent. In one embodiment, the suitable viscosity enhancing agent is
a polymer soluble in PEG. Such suitable viscosity enhancing agents
are well known in the art, e.g., polyvinyl pyrrolidine (hereinafter
"PVP"). PVP is characterized by its viscosity in aqueous solution,
relative to that of water, expressed as a K-value (denoted as a
suffix, e.g., PVP K20), in the range of from about 10 to about 120.
See, e.g., http://www.medicinescomplete.com/mc/excipients/current.
Embodiments of PVP useful in the present invention have a K-value
of about 90 or less. An exemplary such embodiment is PVP K30.
[0034] In one embodiment, the present invention provides a
pharmaceutical composition comprising: [0035] (i)
N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
(Compound 1) or a pharmaceutically acceptable salt thereof; [0036]
(ii) PEG 400; and [0037] (iii) PVP K30.
[0038] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said
N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
is present in an amount from about 0.01% w/w to about 6.5% w/w.
[0039] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said PEG is present in an
amount from about 87.5% w/w to about 99.99% w/w.
[0040] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said PVP K30 is present in an
amount between 0% w/w to about 6% w/w.
[0041] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 97.8 to about 98.0% w/w, for example, about
97.88% w/w), PVP K30 (e.g., from about 1.9 to about 2.1% w/w, for
example, about 2.0% w/w), and Compound 1 (e.g., from about 0.10 to
about 0.15% w/w, for example, about 0.13% w/w).
[0042] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 97.5 to about 98.0% w/w, for example, about
97.75% w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for
example, about 2.0% w/w), and Compound 1 (e.g., from about 0.2 to
about 0.3% w/w, for example, about 0.25% w/w).
[0043] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 97.2 to about 97.8, for example, about 97.50%
w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for example,
about 2.0% w/w), and Compound 1 (e.g., from about 0.4 to about 0.6%
w/w, for example, about 0.50% w/w).
[0044] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 96.5 to about 97.5% w/w, for example, about
97.0% w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for
example, about 2.0% w/w), and Compound 1 (e.g., from about 0.9 to
about 1.1% w/w, for example, about 1.0% w/w).
[0045] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 96.60 to about 96.65% w/w, for example, about
96.63% w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for
example, about 2.0% w/w), and Compound 1 (e.g., from about 1.30 to
about 1.45% w/w, for example, about 1.38% w/w).
[0046] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 96.0 to about 96.3% w/w, for example, about
96.12% w/w), PVP K30 (e.g., from about 1.8 to about 2.0% w/w, for
example, about 2.0% w/w), and Compound 1 (e.g., from about 1.8 to
about 2.2% w/w, for example, about 1.88% w/w).
[0047] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 95.5 to about 96.0% w/w, for example, about
95.75 w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for
example, about 2.0% w/w), and Compound 1 (e.g., from about 2.0 to
about 2.5% w/w, for example, about 2.25% w/w).
[0048] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 95 to about 96% w/w, for example, about 95.5%
w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for example,
about 2.0% w/w), and Compound 1 (e.g., from about 2.3 to about 2.7%
w/w, for example, about 2.50 w/w)
[0049] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 94.5 to about 94.8, for example, about 94.63%
w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for example,
about 2.0% w/w), and Compound 1 (e.g., from about 3.5 to about 4.0%
w/w, for example, about 3.38% w/w).
[0050] In another embodiment, the present invention provides a
pharmaceutical composition, wherein said composition comprises PEG
400 (e.g., from about 93.5 to about 94.5% w/w, for example, about
94.0% w/w), PVP K30 (e.g., from about 1.8 to about 2.2% w/w, for
example, about 2.0% w/w), and Compound 1 (e.g., from about 3.7 to
about 4.3% w/w, for example, about 4.0% w/w).
[0051] In one embodiment, the present invention provides a
pharmaceutical composition comprising: [0052] (i)
N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
(Compound 1) or a pharmaceutically acceptable salt thereof; [0053]
(ii) a suitable PEG lipid; and [0054] (iii) PVP. [0055] In some
embodiments, the PEG lipid has an average molecular weight of from
about 400 to about 600, for example, PEG 400. In some embodiments,
the PVP is PVP K30.
[0056] According to another embodiment, the pharmaceutical
compositions of the present invention comprise a therapeutically
effective amount of Compound 1. The phrase "therapeutically
effective amount" is that amount effective for treating or
lessening the severity of any of the diseases, conditions, or
disorders recited below.
[0057] Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereomeric,
and geometric (or conformational)) forms of the structure; for
example, the R and S configurations for each asymmetric center, (Z)
and (E) double bond isomers, and (Z) and (E) conformational
isomers. Therefore, single stereochemical isomers as well as
enantiomeric, diastereomeric, and geometric (or conformational)
mixtures of the present compounds are within the scope of the
invention. Unless otherwise stated, all tautomeric forms of the
compounds of the invention are within the scope of the invention.
E.g., Compound 1 may exist as tautomers:
##STR00002##
Unless otherwise stated, structures depicted herein are also meant
to include compounds that differ only in the presence of one or
more isotopically enriched atoms. For example, compounds of formula
(I), wherein one or more hydrogen atoms are replaced deuterium or
tritium, or one or more carbon atoms are replaced by a 13C- or
14C-enriched carbon are within the scope of this invention. Such
compounds are useful, for example, as analytical tools, probes in
biological assays, or compounds with improved therapeutic
profile.
[0058] Uses, Formulation and Administration
[0059] Pharmaceutically Acceptable Compositions
[0060] In another aspect of the present invention, pharmaceutically
acceptable compositions are provided, wherein these compositions
comprise an additional pharmaceutically acceptable carrier,
adjuvant or vehicle. In certain embodiments, these compositions
optionally further comprise one or more additional therapeutic
agents.
[0061] It will also be appreciated that certain of the compounds of
present invention can exist in free form for treatment, or where
appropriate, as a pharmaceutically acceptable derivative or a
prodrug thereof. According to the present invention, a
pharmaceutically acceptable derivative or a prodrug includes, but
is not limited to, pharmaceutically acceptable salts, esters, salts
of such esters, or any other adduct or derivative which upon
administration to a patient in need thereof is capable of
providing, directly or indirectly, a compound as otherwise
described herein, or a metabolite or residue thereof.
[0062] As used herein, the term "pharmaceutically acceptable salt"
refers to those salts which are, within the scope of sound medical
judgement, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. A "pharmaceutically acceptable salt" means any
non-toxic salt or salt of an ester of a compound of this invention
that, upon administration to a recipient, is capable of providing,
either directly or indirectly, a compound of this invention or an
inhibitorily active metabolite or residue thereof.
[0063] Pharmaceutically acceptable salts of the compounds of this
invention include those derived from suitable inorganic and organic
acids and bases. Examples of pharmaceutically acceptable, nontoxic
acid addition salts are salts of an amino group formed with
inorganic acids such as hydrochloric acid, hydrobromic acid,
phosphoric acid, sulfuric acid and perchloric acid or with organic
acids such as acetic acid, oxalic acid, maleic acid, tartaric acid,
citric acid, succinic acid or malonic acid or by using other
methods used in the art such as ion exchange. Other
pharmaceutically acceptable salts include adipate, alginate,
ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,
borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N.sup.+(C.sub.1-4alkyl).sub.4 salts. This
invention also envisions the quaternization of any basic
nitrogen-containing groups of the compounds disclosed herein. Water
or oil-soluble or dispersable products may be obtained by such
quaternization. Representative alkali or alkaline earth metal salts
include sodium, lithium, potassium, calcium, magnesium, and the
like. Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine
cations formed using counterions such as halide, hydroxide,
carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and
aryl sulfonate.
[0064] In one embodiment, the present invention provides a method
of treating a CFTR mediated disease, condition, or disorder in a
patient comprising the step of administering to a patient a
pharmaceutical composition according to the present invention.
[0065] A "CFTR-mediated disease" as used herein is a disease
selected from cystic fibrosis, Hereditary emphysema, Hereditary
hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as
Protein C deficiency, Type 1 hereditary angioedema, Lipid
processing deficiencies, such as Familial hypercholesterolemia,
Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage
diseases, such as I-cell disease/Pseudo-Hurler,
Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II,
Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron
dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism,
Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital
hyperthyroidism, Osteogenesis imperfecta, Hereditary
hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI),
Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome,
Perlizaeus-Merzbacher disease, neurodegenerative diseases such as
Alzheimer's disease, Parkinson's disease, Amyotrophic lateral
sclerosis, Progressive supranuclear plasy, Pick's disease, several
polyglutamine neurological disorders such as Huntington,
Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy,
Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as
Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob
disease, Fabry disease, Straussler-Scheinker syndrome, COPD,
dry-eye disease, and Sjogren's disease.
[0066] According to an alternative embodiment, the present
invention provides a method of treating cystic fibrosis comprising
the step of administering to said mammal a pharmaceutical
composition according to the present invention.
[0067] In certain embodiments, the pharmaceutically compositions of
the present invention are useful for treating or lessening the
severity of cystic fibrosis in patients who exhibit residual CFTR
activity in the apical membrane of respiratory and non-respiratory
epithelia. The presence of residual CFTR activity at the epithelial
surface can be readily detected using methods known in the art,
e.g., standard electrophysiological, biochemical, or histochemical
techniques. Such methods identify CFTR activity using in vivo or ex
vivo electrophysiological techniques, measurement of sweat or
salivary Cl.sup.- concentrations, or ex vivo biochemical or
histochemical techniques to monitor cell surface density. Using
such methods, residual CFTR activity can be readily detected in
patients heterozygous or homozygous for a variety of different
mutations, including patients homozygous or heterozygous for the
most common mutation, .DELTA.F508.
[0068] In one embodiment, the pharmaceutically acceptable
compositions of the present invention are useful for treating or
lessening the severity of cystic fibrosis in patients within
certain genotypes exhibiting residual CFTR activity, e.g., class
III mutations (impaired regulation or gating), class IV mutations
(altered conductance), or class V mutations (reduced synthesis)
(Lee R. Choo-Kang, Pamela L., Zeitlin, Type I, II, III, IV, and V
cystic fibrosis Tansmembrane Conductance Regulator Defects and
Opportunities of Therapy; Current Opinion in Pulmonary Medicine
6:521-529, 2000). Other patient genotypes that exhibit residual
CFTR activity include patients homozygous for one of these classes
or heterozygous with any other class of mutations, including class
I mutations, class II mutations, or a mutation that lacks
classification.
[0069] In one embodiment, the pharmaceutically acceptable
composition of the present invention are useful for treating or
lessening the severity of cystic fibrosis in patients within
certain clinical phenotypes, e.g., a moderate to mild clinical
phenotype that typically correlates with the amount of residual
CFTR activity in the apical membrane of epithelia. Such phenotypes
include patients exhibiting pancreatic sufficiency or patients
diagnosed with idiopathic pancreatitis and congenital bilateral
absence of the vas deferens, or mild lung disease.
[0070] The exact amount of Compound 1 required in the
pharmaceutical compositions of the present invention will vary from
subject to subject, depending on the species, age, and general
condition of the subject, the severity of the infection, the
particular agent, its mode of administration, and the like. The
compounds of the invention are preferably formulated in dosage unit
form for ease of administration and uniformity of dosage. The
expression "dosage unit form" as used herein refers to a physically
discrete unit of agent appropriate for the patient to be treated.
It will be understood, however, that the total daily usage of the
compounds and compositions of the present invention will be decided
by the attending physician within the scope of sound medical
judgment. The specific effective dose level for any particular
patient or organism will depend upon a variety of factors including
the disorder being treated and the severity of the disorder; the
activity of the specific compound employed; the specific
composition employed; the age, body weight, general health, sex and
diet of the patient; the time of administration, route of
administration, and rate of excretion of the specific compound
employed; the duration of the treatment; drugs used in combination
or coincidental with the specific compound employed, and like
factors well known in the medical arts. The term "patient", as used
herein, means an animal, preferably a mammal, and most preferably a
human.
[0071] The pharmaceutically acceptable compositions of this
invention can be administered orally at dosage levels of about 0.01
mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about
25 mg/kg, of subject body weight per day, one or more times a day,
to obtain the desired therapeutic effect.
[0072] The pharmaceutical compositions of the present invention may
additionally contain inert diluents commonly used in the art such
as, for example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0073] It will also be appreciated that the pharmaceutically
compositions of the present invention can be employed in
combination therapies, that is, they can be administered
concurrently with, prior to, or subsequent to, one or more other
desired therapeutics or medical procedures. The particular
combination of therapies (therapeutics or procedures) to employ in
a combination regimen will take into account compatibility of the
desired therapeutics and/or procedures and the desired therapeutic
effect to be achieved. It will also be appreciated that the
therapies employed may achieve a desired effect for the same
disorder (for example, a pharmaceutical composition of the present
invention may be administered concurrently with another agent used
to treat the same disorder), or they may achieve different effects
(e.g., control of any adverse effects). As used herein, additional
therapeutic agents normally administered to treat or prevent a
particular disease, or condition, are known as "appropriate for the
disease, or condition, being treated".
[0074] In one embodiment, the additional agent is selected from a
mucolytic agent, bronchodialator, an anti-biotic, an anti-infective
agent, an anti-inflammatory agent, a CFTR modulator other than a
compound of the present invention, or a nutritional agent.
[0075] The amount of additional therapeutic agent present in the
compositions of this invention will be no more than the amount that
would normally be administered in a composition comprising that
therapeutic agent as the only active agent. Preferably the amount
of additional therapeutic agent in the presently disclosed
compositions will range from about 50% to 100% of the amount
normally present in a composition comprising that agent as the only
therapeutically active agent.
[0076] In order that the invention described herein may be more
fully understood, the following examples are set forth. It should
be understood that these examples are for illustrative purposes
only and are not to be construed as limiting this invention in any
manner.
EXAMPLES
Methods & Materials
[0077] Differential Scanning Calorimetry (DSC)
[0078] DSC data was collected on a TA instrument Q1000 equipped
with a 50 position autosampler. The energy and temperature
calibration standard was indium. Samples were heated at a rate of
10.degree. C./min between 20 and 350.degree. C. A nitrogen purge at
30 ml/min was maintained over the sample.
[0079] Between 0.5 and 4 mg of sample was used and all samples run
in a pinhole aluminium pan.
[0080] NMR
[0081] All spectra were collected on a Bruker 400 MHz equipped with
autosampler. Samples were prepared in d.sub.6-DMSO, unless
otherwise stated.
[0082] XRPD (X-Ray Powder Diffraction)
[0083] Bruker AXS C2 GADDS Diffractometer
[0084] X-ray powder diffraction patterns for the samples were
acquired on a Bruker AXS C2 GADDS diffractometer using Cu K.alpha.
radiation (40 kV, 40 mA), automated XYZ stage, laser video
microscope for auto-sample positioning and a HiStar 2-dimensional
area detector. X-ray optics consists of a single Gobel multilayer
mirror coupled with a pinhole collimator of 0.3 mm.
[0085] Beam divergence, i.e. the effective size of the X-ray beam
on the sample, was approximately 4 mm. A .theta.-.theta. continuous
scan mode was employed with a sample to detector distance of 20 cm
which gives an effective 2.theta. range of 3.2-29.8.degree.. A
typical exposure time of a sample would be 120 s.
[0086] Samples run under ambient conditions were prepared as flat
plate specimens using powder as received without grinding.
Approximately 1-2 mg of the sample was lightly pressed on a glass
slide to obtain a flat surface. Samples run under non-ambient
conditions were mounted on a silicon wafer with heat conducting
compound. The sample was then heated to the appropriate temperature
at ca. 20.degree. C./minute and subsequently held isothermally for
ca 1 minute before data collection was initiated.
Synthesis of
N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
(Compound 1)
##STR00003##
[0087] 2-Phenylaminomethylene-malonic acid diethyl ester
[0088] A mixture of aniline (25.6 g, 0.275 mol) and diethyl
2-(ethoxymethylene)malonate (62.4 g, 0.288 mol) was heated at
140-150.degree. C. for 2 h. The mixture was cooled to room
temperature and dried under reduced pressure to afford
2-phenylaminomethylene-malonic acid diethyl ester as a solid, which
was used in the next step without further purification. .sup.1H NMR
(DMSO-d.sub.6) .delta. 11.00 (d, 1H), 8.54 (d, J=13.6 Hz, 1H),
7.36-7.39 (m, 2H), 7.13-7.17 (m, 3H), 4.17-4.33 (m, 4H), 1.18-1.40
(m, 6H).
4-Hydroxyquinoline-3-carboxylic acid ethyl ester
[0089] A 1 L three-necked flask fitted with a mechanical stirrer
was charged with 2-phenylaminomethylene-malonic acid diethyl ester
(26.3 g, 0.100 mol), polyphosphoric acid (270 g) and phosphoryl
chloride (750 g). The mixture was heated to 70.degree. C. and
stirred for 4 h. The mixture was cooled to room temperature and
filtered. The residue was treated with aqueous Na.sub.2CO.sub.3
solution, filtered, washed with water and dried.
4-Hydroxyquinoline-3-carboxylic acid ethyl ester was obtained as a
pale brown solid (15.2 g, 70%). The crude product was used in next
step without further purification.
4-Oxo-1,4-dihydroquinoline-3-carboxylic acid
[0090] 4-Hydroxyquinoline-3-carboxylic acid ethyl ester (15 g, 69
mmol) was suspended in sodium hydroxide solution (2N, 150 mL) and
stirred for 2 h at reflux. After cooling, the mixture was filtered,
and the filtrate was acidified to pH 4 with 2N HCl. The resulting
precipitate was collected via filtration, washed with water and
dried under vacuum to give 4-oxo-1,4-dihydroquinoline-3-carboxylic
acid as a pale white solid (10.5 g, 92%). .sup.1H NMR
(DMSO-d.sub.6) .delta. 15.34 (s, 1H), 13.42 (s, 1H), 8.89 (s, 1H),
8.28 (d, J=8.0 Hz, 1H), 7.88 (m, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.60
(m, 1H).
##STR00004##
Carbonic acid 2,4-di-tert-butyl-phenyl ester methyl ester
[0091] Methyl chloroformate (58 mL, 750 mmol) was added dropwise to
a solution of 2,4-di-tert-butyl-phenol (103.2 g, 500 mmol),
Et.sub.3N (139 mL, 1000 mmol) and DMAP (3.05 g, 25 mmol) in
dichloromethane (400 mL) cooled in an ice-water bath to 0.degree.
C. The mixture was allowed to warm to room temperature while
stirring overnight, then filtered through silica gel (approx. 1 L)
using 10% ethyl acetate-hexanes (.about.4 L) as the eluent. The
combined filtrates were concentrated to yield carbonic acid
2,4-di-tert-butyl-phenyl ester methyl ester as a yellow oil (132 g,
quant.). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.35 (d, J=2.4
Hz, 1H), 7.29 (dd, J=8.5, 2.4 Hz, 1H), 7.06 (d, J=8.4 Hz, 1H), 3.85
(s, 3H), 1.30 (s, 9H), 1.29 (s, 9H).
Carbonic acid 2,4-di-tert-butyl-5-nitro-phenyl ester methyl ester
and Carbonic acid 2,4-di-tert-butyl-6-nitro-phenyl ester methyl
ester
[0092] To a stirring mixture of carbonic acid
2,4-di-tert-butyl-phenyl ester methyl ester (4.76 g, 180 mmol) in
conc. sulfuric acid (2 mL), cooled in an ice-water bath, was added
a cooled mixture of sulfuric acid (2 mL) and nitric acid (2 mL).
The addition was done slowly so that the reaction temperature did
not exceed 50.degree. C. The reaction was allowed to stir for 2 h
while warming to room temperature. The reaction mixture was then
added to ice-water and extracted into diethyl ether. The ether
layer was dried (MgSO.sub.4), concentrated and purified by column
chromatography (0-10% ethyl acetate-hexanes) to yield a mixture of
carbonic acid 2,4-di-tert-butyl-5-nitro-phenyl ester methyl ester
and carbonic acid 2,4-di-tert-butyl-6-nitro-phenyl ester methyl
ester as a pale yellow solid (4.28 g), which was used directly in
the next step.
2,4-Di-tert-butyl-5-nitro-phenol and
2,4-Di-tert-butyl-6-nitro-phenol
[0093] The mixture of carbonic acid
2,4-di-tert-butyl-5-nitro-phenyl ester methyl ester and carbonic
acid 2,4-di-tert-butyl-6-nitro-phenyl ester methyl ester (4.2 g,
14.0 mmol) was dissolved in MeOH (65 mL) before KOH (2.0 g, 36
mmol) was added. The mixture was stirred at room temperature for 2
h. The reaction mixture was then made acidic (pH 2-3) by adding
conc. HCl and partitioned between water and diethyl ether. The
ether layer was dried (MgSO.sub.4), concentrated and purified by
column chromatography (0-5% ethyl acetate-hexanes) to provide
2,4-di-tert-butyl-5-nitro-phenol (1.31 g, 29% over 2 steps) and
2,4-di-tert-butyl-6-nitro-phenol. 2,4-Di-tert-butyl-5-nitro-phenol:
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.14 (s, 1H, OH), 7.34
(s, 1H), 6.83 (s, 1H), 1.36 (s, 9H), 1.30 (s, 9H).
2,4-Di-tert-butyl-6-nitro-phenol: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 11.48 (s, 1H), 7.98 (d, J=2.5 Hz, 1H), 7.66 (d, J=2.4 Hz,
1H), 1.47 (s, 9H), 1.34 (s, 9H).
5-Amino-2,4-di-tert-butyl-phenol
[0094] To a reluxing solution of 2,4-di-tert-butyl-5-nitro-phenol
(1.86 g, 7.40 mmol) and ammonium formate (1.86 g) in ethanol (75
mL) was added Pd-5% wt. on activated carbon (900 mg). The reaction
mixture was stirred at reflux for 2 h, cooled to room temperature
and filtered through Celite. The Celite was washed with methanol
and the combined filtrates were concentrated to yield
5-amino-2,4-di-tert-butyl-phenol as a grey solid (1.66 g, quant.).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.64 (s, 1H, OH), 6.84
(s, 1H), 6.08 (s, 1H), 4.39 (s, 2H, NH.sub.2), 1.27 (m, 18H); HPLC
ret. time 2.72 min, 10-99% CH.sub.3CN, 5 min run; ESI-MS 222.4 m/z
[M+H].sup.+.
N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
##STR00005##
[0096] To a suspension of 4-oxo-1,4-dihydroquinolin-3-carboxylic
acid (35.5 g, 188 mmol) and HBTU (85.7 g, 226 mmol) in DMF (280 mL)
was added Et.sub.3N (63.0 mL, 451 mmol) at ambient temperature. The
mixture became homogeneous and was allowed to stir for 10 min
before 5-amino-2,4-di-tert-butyl-phenol (50.0 g, 226 mmol) was
added in small portions. The mixture was allowed to stir overnight
at ambient temperature. The mixture became heterogeneous over the
course of the reaction. After all of the acid was consumed (LC-MS
analysis, MH+ 190, 1.71 min), the solvent was removed in vacuo.
EtOH was added to the orange solid material to produce a slurry.
The mixture was stirred on a rotovap (bath temperature 65.degree.
C.) for 15 min without placing the system under vacuum. The mixture
was filtered and the captured solid was washed with hexanes to
provide a white solid that was the EtOH crystalate. Et.sub.2O was
added to the material obtained above until a slurry was formed. The
mixture was stirred on a rotovapor (bath temperature 25.degree. C.)
for 15 min without placing the system under vacuum. The mixture was
filtered and the solid captured. This procedure was performed a
total of five times. The solid obtained after the fifth
precipitation was placed under vacuum overnight to provide 8
N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
as a white powdery solid (38 g, 52%).
[0097] HPLC ret. time 3.45 min, 10-99% CH.sub.3CN, 5 min run;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 12.88 (s, 1H), 11.83
(s, 1H), 9.20 (s, 1H), 8.87 (s, 1H), 8.33 (dd, J=8.2, 1.0 Hz, 1H),
7.83-7.79 (m, 1H), 7.76 (d, J=7.7 Hz, 1H), 7.54-7.50 (m, 1H), 7.17
(s, 1H), 7.10 (s, 1H), 1.38 (s, 9H), 1.37 (s, 9H); ESI-MS 393.3 m/z
[M+H].sup.+.
[0098] Set forth below is the characterizing data for Compound
1:
TABLE-US-00001 TABLE 2 Cmd LC-MS LC-RT No. M + 1 min 1 393.2
3.71
[0099] The XRPD spectrum of Compound 1 is shown in FIG. 1.
[0100] .sup.1H NMR data for Compound 1 in shown in FIG. 2.
[0101] The DSC trace of Compound 1 is shown in FIG. 3.
Preparation of Pharmaceutical Compositions
[0102] Materials:
[0103] A Glass bottle for formulation preparation (250 cc amber
glass with teflon lined lid)
[0104] Glass bottle for dose confirmation sample (30 cc amber glass
with Teflon lined lid)
[0105] Stir Plate with temperature probe (ensure probe has been
cleaned)
[0106] New magnetic stir bar
[0107] Spatulas for dispensing excipient and active.
[0108] Step 1: To a clean 250 cc amber glass bottle add the stir
bar to the bottle and record the tare weight of the bottle, stir
bar, label and cap. Tare the bottle with the label and stir
bar.
[0109] Step 2: Dispense targeted amount of PEG400 into the bottle
and accurately weigh. Place the bottle on stir plate and stir to
form a small vortex at the surface of the liquid (.about.300-500
rpm or as necessary). Insert the cleaned temperature probe into the
liquid to a depth of .about.1 cm and raise the setpoint of the
heater to 40.degree. C. Cover the bottle opening with aluminum
foil. Allow the PEG400 to stabilize at 40+/-5.degree. C.
[0110] Step 3: Dispense the required amount of PVP K30 and add to
the stirring PEG400. Add the PVP in a slow stream (over .about.2-3
minutes) and allow the particles to disperse. If the particles
clump, the dissolution will take longer. Cover the bottle opening
with foil and continue stirring the mixture at 40+/-5.degree. C.
The mixture should be sampled at 10 minutes using a small transfer
pipette to determine if the PVP has completely dissolved. The
stirring solution should also be examined for large, undissolved
clumps. If the solution is clear, proceed to the next step. If
undissolved polymer remains, continue stirring. Check for
dissolution every 10 minutes, with a maximum stirring time of 30
minutes total. When complete dissolution is observed, proceed to
the next step. If complete dissolution is not observed within 30
minutes after PVP addition, terminate preparation, discard the
material, and start the preparation from the beginning.
[0111] Step 4: Dispense the required amount of Compound 1 and add
to the stirred PEG/PVP solution in a slow stream. Cover the bottle
opening with foil and continue stirring the mixture at
40+/-5.degree. C. The mixture should be sampled after 30 minutes
using a small transfer pipette to determine if the Compound 1 has
completely dissolved. If the solution is clear after 30 minutes,
proceed to the next step. If undissolved Compound 1 remains,
continue stirring. Check for dissolution every 30 minutes with a
maximum stirring time of 300 minutes (5 hours) after addition of
Compound 1. If complete dissolution is not observed within 300
minutes (5 hours) after addition of Compound 1, terminate
preparation, discard the material, and start the preparation from
the beginning.
[0112] Upon complete dissolution of the Compound 1, remove from the
stir plate, and cap the bottle. The formulation should be
maintained at room temperature until dosing, but must be dosed
within 24 hours of preparation. If precipitation of VX-770 is
observed, do not dose the solution.
[0113] Using the above method, the following ten pharmaceutical
compositions in Table A were prepared:
TABLE-US-00002 TABLE A Composition % PEG % PVP % Cmpd Amount of
Cmpd 1 # 400 w/w K30 w/w 1 w/w per 20 g dose (mg) 1 97.875 2.0
0.125 25 2 97.750 2.0 0.250 50 3 97.500 2.0 0.500 100 4 97.000 2.0
1.000 200 5 96.625 2.0 1.375 275 6 96.125 2.0 1.875 375 7 95.750
2.0 2.25 450 8 95.500 2.0 2.500 500 9 94.625 2.0 3.375 675 10
94.000 2.0 4.000 800
* * * * *
References